九芝堂股份有限公司 2020 年第一季度报告全文 九芝堂股份有限公司 2020 年第一季度报告 2020-024 2020 年 04 月 1 九芝堂股份有限公司 2020 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人李振国、主管会计工作负责人孙卫香及会计机构负责人(会计主 管人员)毛凤云声明：保证季度报告中财务报表的真实、准确、完整。 2 九芝堂股份有限公司 2020 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | |-----------------------------------------------------|---------------------------|---------------------------|------------------------------- ...

Financial Performance - The company reported a total revenue of 1.2 billion RMB for the year 2019, representing a year-on-year increase of 15%[17]. - The net profit attributable to shareholders was 200 million RMB, reflecting a growth of 10% compared to the previous year[17]. - The company's operating revenue for 2019 was ¥3,183,694,789.58, representing a 0.68% increase compared to the previous year[26]. - Net profit attributable to shareholders was ¥192,146,815.99, a decrease of 42.89% from the previous year[26]. - The net profit after deducting non-recurring gains and losses was ¥153,577,965.77, down 40.79% year-on-year[26]. - The net cash flow from operating activities increased significantly by 99.90% to ¥851,290,910.78[26]. - Basic and diluted earnings per share were both ¥0.23, reflecting a decline of 41.03% compared to the previous year[30]. - The weighted average return on equity was 4.70%, down from 7.33% in the previous year[30]. - The total assets of the company reached 3 billion RMB by the end of 2019, with a debt-to-equity ratio of 0.5[17]. - The total assets at the end of 2019 were ¥4,904,747,670.66, a decrease of 6.54% from the previous year[30]. - The net assets attributable to shareholders decreased to ¥3,986,459,014, reflecting a decline of 7.25%[30]. - The company reported a net profit of 192,146,815.99 RMB for 2019, with a distributable profit of 1,193,788,911.48 RMB at year-end[175]. Dividend Distribution - The company proposed a profit distribution plan to distribute a cash dividend of 4 RMB (including tax) for every 10 shares, with no bonus shares issued[7]. - The company distributed a cash dividend of 4.00 RMB per 10 shares for the fiscal year 2019, totaling 335,976,804.80 RMB, which represents 174.85% of the net profit attributable to ordinary shareholders[172]. - The total cash dividend, including other methods such as share repurchase, amounted to 499,958,830.65 RMB, accounting for 260.20% of the net profit attributable to ordinary shareholders[172]. - The cash dividend payout ratio for 2019 was 100% of the total distributable profit[175]. - The company has maintained a consistent cash dividend distribution over the past three years, with the 2018 cash dividend also being 335,976,804.80 RMB, which was 99.85% of the net profit[172]. - The company did not propose any stock dividend distribution for the fiscal year 2019, focusing solely on cash dividends[175]. - The company has a significant amount of retained earnings, with 406,596,062.20 RMB available for distribution after accounting for the cash dividends[175]. Market Strategy and Expansion - The company plans to expand its market presence by increasing its distribution channels and enhancing online sales strategies[6]. - User data indicates a 20% increase in customer engagement through digital platforms over the past year[6]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[6]. - The management provided a performance guidance for 2020, expecting a revenue growth of 12% to 18%[6]. - The company has established a strong marketing network covering various medical institutions and retail pharmacies nationwide, enhancing its competitive position in both OTC and prescription drug markets[54]. - The company is focusing on the re-evaluation of existing products to enhance their clinical value and is developing health products derived from food[58]. - The company plans to leverage the growing health awareness post-pandemic by exploring traditional Chinese medicine services and developing an internet-based health service platform[151]. Research and Development - Research and development efforts are focused on new product lines, particularly in the biopharmaceutical sector, with an investment of 50 million RMB allocated for 2020[6]. - The company is actively engaged in R&D, having undertaken 5 national and provincial major science and technology projects during the reporting period, including the major special project for the Xuexue Tong injection[58]. - The company is committed to innovation, with ongoing projects aimed at developing new drugs and improving existing product standards[59]. - The company aims to accelerate the development of innovative drugs, including the LFG project, with plans to initiate FDA IND application after completing preclinical safety evaluations[144]. - The company is committed to advancing its stem cell research and clinical trials for ischemic stroke, while also exploring new indications for stem cell applications[145]. - The company has made significant progress in its stem cell project through its subsidiary, Beijing Meike, which has received high-tech enterprise certifications[61]. Risk Management - The company has identified key risk factors for future development, including regulatory changes and market competition[6]. - The company faces risks from drug price reductions due to healthcare reforms and procurement policies, which may negatively impact profitability; it plans to enhance product quality and brand value to mitigate this risk[161]. - The company is at risk of raw material supply shortages and price fluctuations, which could significantly affect profitability; it will strengthen market monitoring and strategic reserves[162]. - The company is aware of investment risks associated with its investments in innovative drug development companies and will monitor external and internal factors closely[167]. Corporate Governance - The company’s independent directors fulfilled their responsibilities, ensuring that minority shareholders had opportunities to express their opinions and protect their legal rights[172]. - Li Zhengguo committed to avoiding competition with the company and its controlled enterprises, ensuring no direct or indirect involvement in competing businesses during his tenure as a controlling shareholder[179]. - The company reported that it has maintained independence in operations, assets, finance, and governance, ensuring no misuse of funds or assets by controlling shareholders[182]. - The company has established a complete governance structure to ensure independent decision-making by its board and management[182]. - The company has committed to reducing and regulating related party transactions to protect its interests, ensuring fair agreements are made if unavoidable transactions occur[179]. Industry Outlook - The health industry in China is expected to maintain long-term stable growth, driven by rising income levels, urbanization, and aging population[131]. - The pharmaceutical industry will continue to face strong regulation and price reduction policies, impacting the sales of prescription drugs[134]. - Traditional Chinese medicine is poised for historic development opportunities due to supportive policies and increasing recognition of its value[135]. - The stem cell industry is encouraged by national policies, presenting significant development opportunities[136]. - The gradual popularization of 5G technology will bring profound changes to the traditional Chinese medicine industry, enhancing digital transformation[139].

九芝堂股份有限公司 2019 年第三季度报告全文 九芝堂股份有限公司 2019 年第三季度报告 2019-074 2019 年 10 月 1 九芝堂股份有限公司 2019 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人李振国、主管会计工作负责人孙卫香及会计机构负责人(会计主 管人员)毛凤云声明：保证季度报告中财务报表的真实、准确、完整。 2 九芝堂股份有限公司 2019 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | |-----------------------------------------------------|------------------|-------------------------|------------------|----------------- ...

公告文件 证券代码：000989 证券简称：九芝堂 公告编号：2019-068 九芝堂股份有限公司关于参加湖南辖区上市公司 投资者网上接待日活动的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假记载、误导性陈 述或者重大遗漏负连带责任。 为进一步加强与投资者的互动交流，九芝堂股份有限公司（以下简称"公司"） 将参加由中国证券监督管理委员会湖南监管局、湖南省上市公司协会与深圳市全 景网络有限公司联合举办的"2019 年湖南辖区上市公司投资者网上集体接待日" 活动，现将有关事项公告如下： 本次投资者网上集体接待日活动将通过深圳市全景网络有限公司提供的互 联网平台举行，投资者可以登录"全景·路演天下"网站（http://rs.p5w.net）或关注 微信公众号：全景财经，参与本次投资者网上接待日活动，活动时间为 2019 年 9 月 10 日（星期二）下午 15:00 至 17:00。 届时，公司董事会秘书等相关人员将参加本次活动，通过网络在线交流形式 与投资者进行沟通。欢迎广大投资者积极参与。 特此公告。 九芝堂股份有限公司董事会 2019 年 9 月 6 日 九芝堂股份有限公司 1 ...

九芝堂股份有限公司 2019 年半年度报告全文 九芝堂股份有限公司 2019 年半年度报告 2019-062 2019 年 08 月 1 九芝堂股份有限公司 2019 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人李振国、主管会计工作负责人孙卫香及会计机构负责人(会计主 管人员)毛凤云声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本半年度报告涉及的未来计划、发展战略等前瞻性描述，不构成公司对投 资者的实质承诺，请投资者注意投资风险。 公司已在本报告"第四节、经营情况讨论与分析"中分析了公司未来发展可 能面临的风险因素和应对措施。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 九芝堂股份有限公司 2019 年半年度报告全文 目录 | --- | |--------------------------------------------------------------------- ...

九芝堂股份有限公司 2019 年第一季度报告全文 证券代码：000989 证券简称：九芝堂 公告编号：2019-027 九芝堂股份有限公司 2019 年第一季度报告 2019 年 04 月 1 九芝堂股份有限公司 2019 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 除下列董事外，其他董事亲自出席了审议本次季报的董事会会议 未亲自出席董事姓名 未亲自出席董事职务 未亲自出席会议原因 被委托人姓名 李劲松 董事 工作原因 盛锁柱 公司负责人李振国、主管会计工作负责人孙卫香及会计机构负责人(会计主 管人员)毛凤云声明：保证季度报告中财务报表的真实、准确、完整。 2 九芝堂股份有限公司 2019 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | |-----------------------------------------------------|-- ...

Financial Performance - The company's revenue for 2018 reached 1.5 billion CNY, representing a growth of 10% compared to the previous year[15]. - The net profit attributable to shareholders for 2018 was approximately 200 million CNY, an increase of 12% year-on-year[15]. - The company's operating revenue for 2018 was CNY 3,122,755,711.73, a decrease of 18.61% compared to 2017[23]. - The net profit attributable to shareholders for 2018 was CNY 327,314,236.63, down 54.63% from the previous year[23]. - The net profit after deducting non-recurring gains and losses was CNY 250,211,979.62, a decline of 62.47% year-on-year[23]. - The company's total revenue for the pharmaceutical industry was approximately ¥2.33 billion, a decrease of 27.63% year-over-year[73]. - The gross profit margin for the pharmaceutical industry was 74.30%, down by 2.79% compared to the previous year[73]. - The revenue from the Chinese medicine segment was approximately ¥2.36 billion, reflecting a year-over-year decline of 24.84%[73]. - The company reported a significant increase in other income, which rose by 157.11% to approximately ¥81.83 million, mainly due to increased project subsidies[86]. - The company reported a net profit of 327,314,236.63 RMB for the 2018 fiscal year, with total distributable profits amounting to 1,123,169,654.08 RMB[143]. Cash Dividends - The company reported a cash dividend of 4.00 CNY per 10 shares (including tax) for the 2018 fiscal year[6]. - In 2018, the cash dividend amount was 347,741,694.40 RMB, which accounted for 106.24% of the net profit attributable to ordinary shareholders, indicating a strong return to shareholders[140]. - The total cash dividend, including other forms, reached 540,039,632.93 RMB, representing 164.99% of the net profit attributable to the listed company ordinary shareholders[140]. - The company did not issue any bonus shares for the 2018 fiscal year, maintaining a focus on cash dividends[142]. - The cash dividend distribution reflects the company's commitment to sharing operational results with shareholders while considering future growth[143]. Assets and Liabilities - The total assets of the company as of December 31, 2018, were approximately 1.2 billion CNY, reflecting a year-on-year increase of 15%[15]. - The total assets at the end of 2018 were CNY 5,247,929,616.49, a decrease of 10.70% from the previous year[26]. - The net assets attributable to shareholders decreased by 4.72% to CNY 4,297,879,781.66[26]. - The company's cash and cash equivalents decreased by 10.41% to ¥546,057,048.44, primarily due to share buybacks and payment of funds[93]. - The total amount of accounts receivable decreased by 3.40% to ¥796,241,091.78, reflecting improved sales collection[93]. Research and Development - The company has invested in research and development, allocating 5% of its revenue to enhance product innovation and technology[15]. - Research and development expenses increased by 21.89% to approximately ¥85.43 million, due to increased investment in R&D projects[86]. - The company has applied for 34 patents during the reporting period, with 22 patents granted, including 14 invention patents[63]. - The company has established a research base for raw medicinal materials to control quality from the source[50]. - The company is advancing a stem cell project with a focus on technology transfer, production, and clinical application, aiming for commercialization[127]. Market Strategy and Expansion - The company plans to expand its market presence by launching new products in the herbal medicine sector in 2019[6]. - The company aims to increase its market share by 5% in the next fiscal year through strategic partnerships and acquisitions[6]. - The company is focusing on strategic planning for OTC product tiers over the next three to five years[55]. - The company plans to enhance brand promotion in the OTC sector, aiming to strengthen the market position of key products like An Gong Niu Huang Wan and Fu Guang San[120]. - In 2019, the company plans to expand its e-commerce scale and optimize its supply chain system, emphasizing O2O business development[123]. Corporate Governance and Compliance - The company has committed to maintaining independence in its operations, ensuring that management and financial decisions are made independently from controlling shareholders and related parties[153]. - The company has established a sound corporate governance system to protect creditors' rights[195]. - The company has not reported any significant accounting errors requiring retrospective restatement during the reporting period[158]. - The company has committed to reducing and regulating related party transactions post-restructuring to protect the interests of the listed company[150]. - The company maintains strict adherence to labor laws and regulations to protect employee rights[196]. Operational Efficiency - The company continues to focus on enhancing its operational efficiency and cost management strategies to improve profitability[6]. - The company has improved internal management and resource allocation, enhancing its corporate image and brand influence[65]. - The company will implement comprehensive budget management in 2019 to effectively allocate and control resources across production, finance, and cost management[126]. - The company will continue to strengthen its internal management and optimize organizational structure to improve management efficiency and capabilities[126]. - The company has established a production model based on sales-driven production, ensuring compliance with national GMP standards[43].

九芝堂股份有限公司 2018 年第三季度报告正文 证券代码：000989 证券简称：九 芝 堂 公告编号：2018-097 九芝堂股份有限公司 2018 年第三季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人李振国、主管会计工作负责人孙卫香及会计机构负责人(会计主 管人员)毛凤云声明：保证季度报告中财务报表的真实、准确、完整。 1 九芝堂股份有限公司 2018 年第三季度报告正文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 5,724,783,234.55 | 5,876,584,848.18 | | -2.58% | | 归属于上市公司股东的净资产 | 4,491,580,363.90 | 4,51 ...

九芝堂股份有限公司 2018 年半年度报告全文 证券代码：000989 证券简称：九芝堂 公告编号：2018-062 九芝堂股份有限公司 2018 年半年度报告 2018 年 07 月 1 九芝堂股份有限公司 2018 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人李振国、主管会计工作负责人孙卫香及会计机构负责人(会计主 管人员)毛凤云声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 4 九芝堂股份有限公司 2018 年半年度报告全文 本半年度报告涉及的未来计划、发展战略等前瞻性描述，不构成公司对投 资者的实质承诺，请投资者注意投资风险。 公司已在本报告"第四节、经营情况讨论与分析"中分析了公司未来发展可 能面临的风险因素和应对措施。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 第一节 | 重要提示、目录和释义 2 | | --- | --- | | 第二节 | 公司简介和主要财 ...

九芝堂股份有限公司 2018 年第一季度报告正文 证券代码：000989 证券简称：九 芝 堂 公告编号：2018-045 九芝堂股份有限公司 2018 年第一季度报告正文 第一节 重要提示 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 839,303,390.88 | 684,717,265.51 | 22.58% | | 归属于上市公司股东的净利润（元） | 142,326,508.80 | 132,976,115.52 | 7.03% | | 归属于上市公司股东的扣除非经常性损 益的净利润（元） | 122,667,099.33 | 127,750,756.18 | -3.98% | | 经营活动产生的现金流量净额（元） | -24,792,892.32 | 58,364,678.80 | -142.48% | | 基本每股收益（元/股） | 0.1637 | 0.1530 | 6.99% | | 稀释每股收益（元/股） | 0.1637 | 0.1530 | 6.99% | | 加权平均净资产收益率 | 3. ...